RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
REPLIGEN CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$176.43+1.01 (+0.58%)
Close on Oct 19, 2026
- Market cap
- $9.99B
- P/E (TTM)
- 205.2
- Dividend yield
- –
REPLIGEN CORP revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $737.96M | $634.18M | $631.98M | $801.18M | $670.32M | $366.14M | $270.10M | $193.89M | $141.09M | $104.44M | 100.0% | +16.4% |
| Filtration Products [Member] | $402.79M | $372.96M | $341.38M | $495.93M | $403.51M | $174.85M | $119.46M | $90.59M | $49.05M | $19.77M | 54.6% | +8.0% |
| Chromatography Products [Member] | $153.18M | $122.81M | $126.63M | $131.68M | $91.04M | $70.68M | $60.66M | $45.33M | $36.31M | $29.52M | 20.7% | +24.7% |
| Proteins Products [Member] | $97.44M | $74.43M | $103.46M | $114.32M | $123.71M | $83.32M | $69.00M | $54.38M | $53.97M | – | 13.2% | +30.9% |
| Process Analytics Products [Member] | $81.24M | $59.30M | $56.82M | $53.51M | $48.02M | $33.35M | $16.41M | – | – | – | 11.0% | +37.0% |
| Other products [Member] | $3.32M | $4.68M | $3.69M | $5.74M | $4.05M | $3.95M | $4.56M | $3.60M | $1.76M | $431.00K | 0.4% | -29.0% |
| Royalty and Other Revenue | $296.00K | $261.00K | $383.00K | $353.00K | $215.00K | $124.00K | $148.00K | $141.00K | $147.00K | $100.00K | 0.0% | +13.4% |
| Protein products | – | – | – | – | – | – | – | $54.38M | $53.97M | $54.72M | – | – |
By region
From the segment and revenue-disaggregation notes of Repligen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.